These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 25446553)

  • 1. Impact of pharmacologic interventions--treating endothelial dysfunction and group 2 pulmonary hypertension.
    Guazzi M; Gomberg-Maitland M; Naeije R
    Prog Cardiovasc Dis; 2015; 57(5):473-9. PubMed ID: 25446553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Group 2 PH: Medical Therapy.
    Guazzi M; Labate V
    Prog Cardiovasc Dis; 2016; 59(1):71-7. PubMed ID: 27389809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure.
    Yin J; Kukucka M; Hoffmann J; Sterner-Kock A; Burhenne J; Haefeli WE; Kuppe H; Kuebler WM
    Circ Heart Fail; 2011 Mar; 4(2):198-206. PubMed ID: 21216837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment for pulmonary hypertension of left heart disease.
    Guazzi M; Vitelli A; Labate V; Arena R
    Curr Treat Options Cardiovasc Med; 2012 Aug; 14(4):319-27. PubMed ID: 22711417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of pulmonary hypertension with left heart disease: a concise review.
    Desai A; Desouza SA
    Vasc Health Risk Manag; 2017; 13():415-420. PubMed ID: 29158679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of secondary pulmonary hypertension with bosentan after left ventricular assist device implantation.
    LaRue SJ; Garcia-Cortes R; Nassif ME; Vader JM; Ray S; Ravichandran A; Rasalingham R; Silvestry SC; Ewald GA; Wang IW; Schilling JD
    Cardiovasc Ther; 2015 Apr; 33(2):50-5. PubMed ID: 25759010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary hypertension associated with left heart disease.
    Adir Y; Amir O
    Semin Respir Crit Care Med; 2013 Oct; 34(5):665-80. PubMed ID: 24037633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary hypertension due to left heart diseases.
    Vachiéry JL; Adir Y; Barberà JA; Champion H; Coghlan JG; Cottin V; De Marco T; Galiè N; Ghio S; Gibbs JS; Martinez F; Semigran M; Simonneau G; Wells A; Seeger W
    J Am Coll Cardiol; 2013 Dec; 62(25 Suppl):D100-8. PubMed ID: 24355634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary hypertension in heart failure with preserved ejection fraction.
    Guazzi M; Gomberg-Maitland M; Arena R
    J Heart Lung Transplant; 2015 Mar; 34(3):273-81. PubMed ID: 25577563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension.
    Ghofrani HA; Pepke-Zaba J; Barbera JA; Channick R; Keogh AM; Gomez-Sanchez MA; Kneussl M; Grimminger F
    J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):68S-72S. PubMed ID: 15194181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of β-Blockers in Pulmonary Hypertension.
    Perros F; de Man FS; Bogaard HJ; Antigny F; Simonneau G; Bonnet S; Provencher S; Galiè N; Humbert M
    Circ Heart Fail; 2017 Apr; 10(4):. PubMed ID: 28364092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Pulmonary Hypertension in the Context of Heart Failure with Preserved Ejection Fraction.
    Kozaily E; Akdogan ER; Dorsey NS; Tedford RJ
    Curr Hypertens Rep; 2024 Jul; 26(7):291-306. PubMed ID: 38558124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation and Management of Pulmonary Hypertension in Kidney Transplant Candidates and Recipients: Concepts and Controversies.
    Lentine KL; Villines TC; Axelrod D; Kaviratne S; Weir MR; Costa SP
    Transplantation; 2017 Jan; 101(1):166-181. PubMed ID: 26985742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary hypertension and right ventricular function in advanced heart failure.
    Kalogeropoulos AP; Vega JD; Smith AL; Georgiopoulou VV
    Congest Heart Fail; 2011; 17(4):189-98. PubMed ID: 21790969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?
    Correale M; Ferraretti A; Monaco I; Grazioli D; Di Biase M; Brunetti ND
    Vasc Health Risk Manag; 2018; 14():253-264. PubMed ID: 30323613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary hypertension in heart failure.
    Guglin M; Khan H
    J Card Fail; 2010 Jun; 16(6):461-74. PubMed ID: 20610227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary hypertension: a correct diagnosis for a suitable therapy in scleroderma patients.
    Giordano N; Montella A; Corallo C; Ruocco G; Chirico C; Palazzuoli A; Nuti R; Pecetti G
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S182-9. PubMed ID: 26339897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Off-label use of pulmonary vasodilators after left ventricular assist device implantation: Calling in the evidence.
    Papathanasiou M; Ruhparwar A; Kamler M; Rassaf T; Luedike P
    Pharmacol Ther; 2020 Oct; 214():107619. PubMed ID: 32599009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current therapeutics and practical management strategies for pulmonary arterial hypertension.
    Agarwal R; Gomberg-Maitland M
    Am Heart J; 2011 Aug; 162(2):201-13. PubMed ID: 21835279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Building the case for novel clinical trials in pulmonary arterial hypertension.
    Ryan JJ; Rich JD; Maron BA
    Circ Cardiovasc Qual Outcomes; 2015 Jan; 8(1):114-23. PubMed ID: 25604559
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.